Quick Answer
SANGAMO THERAPEUTICS, INC reported Operating Income of -$121.24 million for fiscal year 2025.
SANGAMO THERAPEUTICS, INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$121.24M | -16.6% |
| 2024 | -$103.97M | +62.1% |
| 2023 | -$274.00M | -36.1% |
| 2022 | -$201.28M | -9.8% |
| 2021 | -$183.34M | -41.5% |
| 2020 | -$129.55M | -23.2% |
| 2019 | -$105.18M | -36.3% |
| 2018 | -$77.15M | -36.9% |
| 2017 | -$56.36M | +22.3% |
| 2016 | -$72.56M | -54.9% |
| 2015 | -$46.86M | -75.0% |
| 2014 | -$26.78M | -0.3% |
| 2013 | -$26.71M | -20.3% |
| 2012 | -$22.20M | +38.0% |
| 2011 | -$35.82M | -43.7% |
| 2010 | -$24.93M | -28.5% |
| 2009 | -$19.40M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$35.55M | -434.4% | -99.1% |
| June 30, 2025 | -$17.86M | +51.9% | +39.7% |
| March 31, 2025 | -$29.63M | +42.5% | -378.7% |
| September 30, 2024 | $10.63M | +110.0% | +128.7% |
| June 30, 2024 | -$37.08M | +70.0% | +28.0% |
| March 31, 2024 | -$51.53M | -385.7% | +51.6% |
| September 30, 2023 | -$106.41M | -93.8% | +13.9% |
| June 30, 2023 | -$123.57M | -170.2% | -785.2% |
- SANGAMO THERAPEUTICS, INC showed a decrease of -16.6% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, SANGAMO THERAPEUTICS, INC’s operating income has declined by 524.9% (from -$19.40 million to -$121.24 million).
- The most recent figure is from SANGAMO THERAPEUTICS, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: